Return to search results.
Complete title: Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults
|Research Study Number||2317.00|
|Principal Investigator||Guang-Shing Cheng|
Research Study Description
- Bronchiolitis obliterans is a form of chronic graft-versus-host disease (GVHD) that sometimes develops after stem cell transplantation (SCT) or bone marrow transplantation (BMT).
- In bronchiolitis obliterans, immune cells that normally fight infections attack the lungs of the transplant recipient, causing destruction of lung tissue and fibrosis (scarring). When fibrosis develops, the lungs cannot work properly.
- Montelukast (Singulair) is a drug that has been used for many years to treat asthma. Its use as a treatment for bronchiolitis obliterans is experimental.
- To see if montelukast improves or stabilizes lung function in patients who develop bronchiolitis obliterans after BMT or SCT.
- To assess the safety of montelukast in patients with bronchiolitis obliterans after BMT or SCT
- To see if montelukast affects the cells that damage the lungs.
- To see if montelukast improves other forms of chronic GVHD, quality of life, and overall survival in patients with bronchiolitis obliterans after BMT or SCT.
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Chronic Graft Versus Host Disease (cGVHD)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.